ClearCut Medical

ClearCut Medical Overview

ClearCut Medical develops and commercializes solutions designed for the accurate and effective removal of cancer. Its technology is based on magnetic resonance imaging (MRI) protocols that enable accurate and rapid surface imaging for real-time margin assessment of excised tissue in the operating room. The companys ClearSight MRI System is focused on breast cancer lumpectomies, enabling an intraoperative margin assessment of surgically removed lumps. The system is expected to significantly improve surgical outcomes and reduce re-excision rates. Future applications include prostate and breast cancer biopsies and skin cancer excisions, as well as additional oncological applications, including colorectal and lung cancers. The device is CE marked and has shown industry-leading accuracy in comparison to histopathology in two multi-center trials. ClearCut Medical is initially focusing on breast-conserving surgery, with a TAM of $1.2 billion in the U.S. and Europe. In March 2018, the Australian Department of Healths Therapeutic Goods Administration (TGA) issued a Therapeutic Goods Certificate for the ClearSight MRI System. ClearCut Medicals distribution partner, Surgeon Choice Australia Pty Ltd, will supply the product to key surgical cancer centers in Australia.

Cumulative Funding Raised Over Time ($)

Latest News

Jul 17, 2019 · www.prnewswire.com

growth-positive

ClearCut Medical Appoints Jim Buck as President & CEO

ClearCut Medical Inc. has announced the appointment of Jim Buck as President & CEO, replacing Armin Schon, PhD. This appointment marks the companys transition from a development stage to a commercial stage. Jim Buck brings extensive experience in developing and commercializing medical technologies. ClearCut Medical is a medical device company focused on improving cancer patient care through its intra-operative MRI technology. The company has developed the ClearSight™ system for real-time tissue margin assessment. The system aims to reduce the need for repeat surgery in Lumpectomy patients. The European launch of the ClearSight™ system is planned for later this year.

Management Changes

May 29, 2015 · www.businesswire.com

Clear-Cut Medical Raises Further Funding for Clinical Trials, Commercial Support and Product Development

Nov 15, 2011 · www.globes.co.il

growth-positive

MRI co Clear Cut Medical raises NIS 2.8m

Clear Cut Medical Ltd., a company developing a compact MRI device for assisting breast cancer surgery, has raised NIS 2.8 million from new and current investors. The companys MRI can detect the surgical margins during the procedure to ensure excision of the entire tumor. The financing resulted in Gefen Biomed Investments Ltd.s share in the company falling from 29.8% to 24%. Clear Cut Medicals device is similar to the device developed by Dune Medical Devices Ltd. for the immediate assessment of breast cancer on the margin of excised tissue.

Investment

Funding

Team Members

4

Employees: 11-50

Web & Social Links

Locations

David Fikes St 5, Rehovot, Israel

6803 Rachel Ridge Court, Maple Plain, MN, USA

Photos & Videos

1 item(s)

ClearCut Medical Internal

Recent Updates

No update log entries.

Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.

Admin Info